The risk of renal disease is increased in lambda myeloma with bone marrow amyloid deposits
Authors:
Open Access
- 1 March 2017
- journal article
- research article
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 8, 29-34
Abstract
The risk of renal disease is increased in lambda myeloma with bone marrow amyloid deposits Piotr Kozlowski,1 Scott Montgomery,2–4 Rahel Befekadu,5 Victoria Hahn-Strömberg6 1Department of Medicine, School of Medical Sciences, Örebro University, Örebro, Sweden; 2Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden; 3Clinical Epidemiology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; 4Department of Epidemiology and Public Health, University College London, London, UK; 5Department of Transfusion Medicine, School of Medical Sciences, Örebro University, Örebro, Sweden; 6Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden Background: Light chain amyloidosis (AL) is a rare deposition disease and is present in 10–15% of patients with myeloma (MM). In contrast to symptomatic AL in MM, presence of bone marrow (BM) amyloid deposits (AD) in MM is not connected to kidney damage. Renal AD but not BM-AD occur mostly in MM with lambda paraprotein (lambda MM). Methods: We investigated amyloid presence in BM clots taken at diagnosis in 84 patients with symptomatic MM and compared disease characteristics in MM with kappa paraprotein (kappa MM)/lambda MM with and without BM-AD. Results: Lambda MM with BM-AD was compared with kappa MM without BM-AD, kappa MM with BM-AD, and lambda MM without BM-AD: lambda MM with BM-AD patients had a significantly higher mean creatinine level (4.23 mg/dL vs 1.69, 1.14, and 1.28 mg/dL, respectively) and a higher proportion presented with severe kidney failure (6/11 [55%] vs 6/32 [19%], 1/22 [5%], and 3/19 [16%], respectively). Proteinuria was more common in lambda MM with BM-AD patients compared with kappa MM without BM-AD patients (8/11 [73%] vs 5/32 [16%], respectively). Conclusion: Kidney damage was more common in lambda MM with BM-AD indicating presence of renal AD. Keywords: plasma cells, neoplasms, amyloidosis, renal insufficiency, proteinuriaKeywords
This publication has 19 references indexed in Scilit:
- Amyloid Deposits in the Bone Marrow of Patients with Immunoglobulin Light Chain Amyloidosis Do Not Impact Stem Cell Mobilization or EngraftmentTransplantation and Cellular Therapy, 2012
- Clinicopathologic Correlations in Multiple Myeloma: A Case Series of 190 Patients With Kidney BiopsiesAmerican Journal of Kidney Diseases, 2012
- Screening and Differential Diagnosis of Renal Light Chain-Associated DiseasesKidney and Blood Pressure Research, 2011
- Cytological and histological detection of amyloid deposits in bone marrow of patients affected by multiple myelomaLeukemia & Lymphoma, 2011
- Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple MyelomaMayo Clinic Proceedings, 2010
- Amyloid in bone marrow smears of patients affected by multiple myelomaAnnals of Hematology, 2009
- Bone Marrow Core Biopsy Specimens in AL (Primary) Amyloidosis: A Morphologic and Immunohistochemical Study of 100 CasesAmerican Journal of Clinical Pathology, 2003
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003
- Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathiesNephrology Dialysis Transplantation, 1998
- Primary systemic amyloidosis: clinical and laboratory features in 474 cases.1995